What if an Alzheimer’s treatment had been under our noses all this time?

Qualified for “Miracle pill”, Viagra will not have deserved the name as much as it does today. A study found that it would greatly reduce the risk of Alzheimer’s. The results of the study made public in the journal Nature Aging indicate that the sildenafil contained in viagra would reduce the risk of developing the disease to 69%. A group of researchers from Case Western Reserve, the Cleveland Clinic, and Indiana University conducted the study.

brain missing a puzzle

Credit: HealthDay

Scientists have studied the effects of drugs that suppress the spread of beta-amyloid and tau, two proteins that develop in the brains of people with Alzheimer’s. On several tests, sildenafil has shown particular promise.

Although this news is a source of hope, voices are being raised to call for some caution.

A turning point in the treatment of Alzheimer’s

For their research, the scientists analyzed a battery of data biological and genetic. They also studied prescription insurance claims to establish that patients who used Viagra had their risk of Alzheimer’s decrease significantly.

Clinical trials compared to other drugs such as losartan, metformin, have shown that viagra is more effective. In addition, researchers have observed that sildenafil slows down the risk of the growth of certain diseases conducive to the development of Alzheimer’s.

“In particular, we found that the use of sildenafil reduced the likelihood of developing Alzheimer’s disease in people with coronary artery disease, hypertension and type 2 diabetes, all of which are co-morbidities significantly associated with the risk of the disease, as well. than in those who do not suffer from it. “

Feixiong Cheng, researcher at the Institute of Genomic Medicine at the Cleveland Clinic

The mistrust of some scientists

If the results obtained with sildenafil are encouraging, several scientists were not enthusiastic. They call for restraint pending further in-depth research. Viagra cannot be prescribed alone in therapy against Alzheimer’s disease. This reluctance is justified by the fact that studies must also extend to women.

“Because Alzheimer’s disease is a complex disease caused by many factors, multi-target drugs or combination therapies targeting multiple disease pathways may provide better clinical benefits. “

Feixiong Cheng, Institute of Genomic Medicine, Cleveland Clinic

Leave a Comment

Your email address will not be published.